Laidlaw’s James Ahern Named to Crain’s New York Notable Leaders in Finance 2024
dan2024-03-26T20:20:57-04:00EyePoint Pharmaceuticals Announces Closing of Upsized Public Offering and Full Exercise of Option to Purchase Additional Shares
EyePoint Pharmaceuticals Announces Closing of Upsized Public Offering and Full Exercise of Option to Purchase Additional Shares
dan2023-12-12T18:34:27-05:00EyePoint Pharmaceuticals Announces Closing of Upsized Public Offering and Full Exercise of Option to Purchase Additional Shares
Laidlaw served as Co-Manager on the $129,000,000 Common Stock and Concurrent Private Placement for Soleno Therapeutics (SLNO)
dan2023-12-05T23:49:34-05:00Laidlaw served as Co-Manager on the $129,000,000 Common Stock and Concurrent Private Placement for Soleno Therapeutics (SLNO)
Laidlaw acts as Co-Manager on the $287,500,000 Follow-On Offering for Viking Therapeutics.
dan2023-03-31T03:30:28-04:00Laidlaw is pleased to act as Co-Manager on Vikings 287.5mm dollar offering. Laidlaw Capital Markets was the Sole Book Runner on Viking’s 27.6mm dollar IPO in 2015. VKTX is now over a one billion dollar company brought to market off the Laidlaw launchpad. Read Article
Laidlaw acts as Exclusive Introducing Broker on NLS Pharmaceutics’ Closing of Initial Tranche of US$10.0 Million Purchase Agreement with BVF Partners L.P.
dan2022-12-19T05:42:02-05:00On December 14, 2022, NLS Pharmaceutics (NASDAQ:NLSP,)(NASDAQ:NLSPW) announced the closing of its previously publicized purchase agreement with BVF Partners L.P. ("BVF") comprised of an initial closing of $10 million in exchange for 11,494,253 common shares (or equivalents), representing a purchase price per share of $0.87.As part of the financing, in a second potential closing, BVF will have Read More...
Laidlaw acts as Sole Placement Agent on the $4,000,000 NLS Pharmaceutics Ltd. Private Placement
dan2022-10-05T17:16:08-04:00Laidlaw is pleased to have acted as the Sole Placement Agent on the $4,000,000 Private Placement for NLS Pharmaceutics. Read Article
Laidlaw acts as Sole Book-Runner on the $5,750,000 Silo Pharma, Inc. Follow-On Offering
dan2022-09-29T13:05:14-04:00Silo Pharma Announces Closing of $5.75 Million Public Offering of Common Stock, Nasdaq Listing, and Full Exercise of Underwriter’s Over-Allotment Option: Read Article
Laidlaw Capital Markets is pleased to announce the closing of its expanded and oversubscribed $10,000,000 financing for Perfect Moment.
dan2022-07-20T20:35:11-04:00Perfect Moment is a luxury sportswear brand that has become known as an iconic staple in winter wear. The Perfect Moment collections marry the extreme demands of nature with the world of fashion and can be found at Selfridges, Net-A-Porter, Matches, Saks Fifth Avenue, Neiman Marcus, Bloomingdales and FWRD. Read Article Read More...
Laidlaw acts as Sole-Book Runner on the $3,500,000 BioSig Technologies’ Follow-On Transaction.
dan2022-06-28T13:27:15-04:00Laidlaw Capital Markets is pleased to have acted as Sole-Book Runner on the $3,500,000 Common Stock transaction for BioSig Technologies (BSGM). Read Article
Laidlaw acts as Underwriter on the $367,886,900 Cohen & Steers Real Estate Opportunities and Income Fund Offering
dan2022-02-28T02:55:06-05:00Laidlaw Capital Markets is pleased to have acted as Underwriter on the $367,886,900 Cohen & Steers Real Estate Opportunities and Income Fund Offering alongside Bank of America, Morgan Stanley, Raymond James, UBS, & Wells Fargo. Read article: https://www.prnewswire.com/news-releases/cohen--steers-real-estate-opportunities-and-income-fund-rlty-raises-305-million-301490198.html
Stay In Touch